xRAN Forum Releases Second Open Fronthaul Control, User and Synchronization Plane Specification and First Open Fronthaul Management Plane Specification
The xRAN Forum (xRAN) today announced the Board’s approval and public availability of the xRAN Fronthaul Control, User and Synchronization (CUS) Plane Specification Version 2.0 and the xRAN Fronthaul Management Plane (MP) Specification Version 1.0. The specifications have been designed to allow a wide range of vendors to develop innovative, best-of-breed RRUs and BBUs for a wide range of deployment scenarios, which can be easily integrated with virtualized infrastructure & management systems using standardized data models.
The new specifications deliver on important operator member requirements. All xRAN operator members extend well deserved credit and gratitude to the xRAN members who made contributions and facilitated strong collaboration within the xRAN Forum Front Haul Working Group, chaired by Verizon Communication.
The xRAN Forum fosters a growing ecosystem of innovative and interoperable RAN products catering to the varied needs of the Forum’s operator members. Interfaces defined by the xRAN Fronthaul Specification enable efficient deployment of advanced technologies like Massive MIMO & Virtualized RAN with support for LTE and NR.
The second major version of CUS-plane specification incorporates several enhancements over the first version including:
- Support for 2 radio categories (A and B) to enable both simple and more complex functionality leveraging largely the same interface specification
- Additional compression modes to provide increased fronthaul bandwidth savings
- Support for critical items such as synchronization and timing to enable commercialization and interoperability in deployments
- Support for additional LTE system features like LAA, NB-IOT, including improved efficiency in parsing of U-plane packets
The first version of M-plane specification is a significant milestone for the industry. It provides an open multi-vendor M-plane model for radios based on standardized modern protocols like NETCONF/YANG and includes key capabilities:
- Support for features and capabilities in v1.0 of CUS specification and several enhancements in v2.0 of CUS specification
- Flexible management architecture providing support for traditional hierarchical and hybrid (multiple NETCONF clients or EMS can directly communicate with radio) deployment models
- A comprehensive YANG model developed for 4G & 5G radios building upon industry accepted data models
A registration link to download the complete specifications is available on the xRAN website.
About xRAN Forum
The xRAN Forum was formed to develop, standardize and promote an open alternative to the traditionally closed, hardware-based RAN architecture. xRAN fundamentally advances RAN architecture in three areas – decouples the RAN control plane from the user plane, builds a modular eNB software stack that operates on common-off-the-shelf (COTS) hardware and publishes open north- and south-bound interfaces to the industry.
Since its founding the xRAN Forum has gained tremendous industry momentum with leadership from operators AT&T, Deutsche Telekom, JIO, KDDI, NTT DOCOMO, SK Telecom, Sprint, Telefonica, Telstra and Verizon. At the same time, xRAN has grown its contributing member base with strong representation from the vendor community including: Altiostar, Amdocs, Aricent, ASOCS, Blue Danube, Broadcom, Ciena, Cisco, Commscope, Fujitsu, Intel, Keysight Technologies, Mavenir, NEC, Netsia, Nokia, Pivotal Commware, Radisys, Samsung, Stanford University, University of Sydney, and VIAVI Solutions
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Manchester United and True Religion Launch Denim Range19.10.2018 20:37 | Tiedote
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10 | Tiedote
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 14:54 | Tiedote
Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr
Tradeshift Announces Q3 2018 Results19.10.2018 14:00 | Tiedote
Tradeshift, the leader in supply chain payments and marketplaces, today announced results from the third quarter of 2018, marking the tenth quarter in a row of successive growth and beating targets. Tradeshift’s third quarter growth stats announced today include: YoY revenue grew 400 percent (trailing 12 months) YoY new bookings grew 284 percent YoY gross merchandise volume (GMV) grew 262 percent New total contract value grew by $47M in Q3 Tradeshift’s customer roster continued strong growth this quarter adding 27 new customers, including Hertz, Shiseido, ECU, and Fortune 500 leaders in retail apparel, agriculture, engineering and construction, hospitality, travel and food delivery. Tradeshift also expanded its app ecosystem by adding a key partnership with Coface, a global credit insurer. Coface has announced a new app solution on the Tradeshift platform offering risk and business information services to help businesses make decisions by ensuring greater financial transparency between
Schlumberger Announces Third-Quarter 2018 Results19.10.2018 14:00 | Tiedote
Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme